Therapeutic plasma exchange removes plasma containing pro-aging factors and replaces it with albumin or donor products. It is an established, FDA-cleared treatment for conditions like Guillain-Barre and TTP; for longevity, the evidence is one 2025 randomized placebo-controlled trial (n=44) in which TPE plus IVIG cut composite biological age by 2.6 years across 36 epigenetic clocks. Effects waned within months, the trial had no IVIG-only arm, and sicker participants benefited most. Long-term safety of repeated use is unknown.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Does plasma exchange reduce biological age?
One 2025 randomized placebo-controlled trial (n=44) found weekly TPE reduced composite biological age by 1.3 years and TPE plus IVIG by 2.6 years, measured across 36 epigenetic clocks. The benefit faded within about two months and there was no IVIG-only arm, so the contribution of the procedure itself is unclear.1
Is plasma exchange FDA-approved?
The procedure is FDA-cleared and established for specific indications such as Guillain-Barre syndrome, myasthenia gravis and TTP. Longevity use is off-label and not FDA-approved, and IVIG is approved for immunodeficiency, not aging.
Why would removing plasma slow aging?
Heterochronic parabiosis studies found that old blood contains pro-aging factors: young blood rejuvenated old mice, old blood impaired neurogenesis in young mice, and simply exchanging old plasma for saline and albumin improved multiple tissues. The working model is that diluting harmful circulating factors matters more than adding young ones.234
Is therapeutic plasma exchange safe?
As a medical procedure it is well-characterized: common issues are citrate-related hypocalcemia, hypotension and allergic reactions, with rare anaphylaxis or arrhythmia. The unanswered risks are for longevity use specifically: protein, immunoglobulin and clotting-factor depletion with repeated sessions, and no long-term data at all.
What would change this rating?
A larger randomized trial with an IVIG-only arm and longer follow-up. The single existing trial's effects were transient, so durability and the mechanism split between TPE and IVIG are the open questions.1
Core thesis: Therapeutic plasma exchange (TPE) removes a person's blood plasma — which accumulates pro-aging inflammatory factors, senescence-associated secretory phenotype (SASP) proteins, and other deleterious molecules with age — and replaces it with albumin/saline or donor plasma. Grounded in decades of heterochronic parabiosis research showing that young blood rejuvenates old tissues, TPE is now being tested as a longevity intervention. The first human clinical trial (Fuentealba et al., Aging Cell, 2025) demonstrated that TPE combined with IV immunoglobulin (IVIG) reduced biological age by an average of 2.6 years as measured by 36 epigenetic clocks and multi-omic biomarkers. This is an experimental therapy with real risks and limited long-term data.
02Theoretical Foundation: Young Blood, Old Blood
Heterochronic Parabiosis
The conceptual basis for TPE in longevity comes from heterochronic parabiosis — surgically connecting the circulatory systems of a young and old mouse so they share blood.
| Study | Key Finding | Significance |
|---|---|---|
| Conboy et al. 2005 (Nature) | Exposure of old mice to young blood rejuvenated aged progenitor cells in liver, skeletal muscle | Revived the field; proved systemic factors drive aging |
| Villeda et al. 2011 (Nature) | Old blood impaired neurogenesis and cognition in young mice | Showed old blood contains pro-aging factors |
| Rebo et al. 2016 (Nature Communications) | Neutral blood exchange (not full parabiosis) improved multiple tissues in old mice | Demonstrated plasma itself, not cells, drives effect |
| Sviercovich et al. 2024 (Ageing Research Reviews) | Old blood has age-related increase in protein production and "noise" | Identified proteostasis disruption as mechanism |
Swipe table →
The "Old Blood" Hypothesis
The current model is that aging blood plasma accumulates: - SASP proteins from senescent cells (pro-inflammatory cytokines: IL-6, TNF-α, TGF-β) - Pro-aging signaling molecules (CCL11/eotaxin, β2-microglobulin) - Inflammatory mediators driving inflammaging - Microplastics and environmental toxins (removed by TPE) - Degraded extracellular matrix fragments
TPE removes these circulating factors, diluting the pro-aging systemic milieu. Unlike parabiosis, TPE does not add "young" factors — it purely dilutes old ones, suggesting that removal of deleterious factors may be more important than addition of beneficial ones.
Key insight: The Conboy lab argues that the rejuvenating effect of young blood in parabiosis is actually due to dilution of old blood factors, not transfer of young factors. Their neutral blood exchange experiments support this — old mice improved just from having their plasma replaced with saline/albumin.
03The First Human Trial: Circulate Health / Buck Institute
Fuentealba et al. 2025 (Aging Cell)
This is the landmark study — the first randomized, single-blind, placebo-controlled trial of TPE for biological aging in humans.
Citation: Fuentealba M, Kiprov D, Schneider K, et al. "Multi-omics analysis reveals biomarkers that contribute to biological age rejuvenation in response to single-blinded randomized placebo-controlled therapeutic plasma exchange." Aging Cell. 2025;24(7):e70103. doi:10.1111/acel.70103
Study Design
- Participants: 44 adults completed the study (average age in their 60s)
- Design: Single-blind, placebo-controlled, randomized
- Groups: 1. Weekly TPE for 6 months 2. Biweekly TPE for 3 months 3. Biweekly TPE + IVIG for 3 months 4. Sham/placebo group
- Measurements: 36 epigenetic clocks (including GrimAge, Horvath, Hannum, DamAge), proteomics, metabolomics, immune cell phenotyping
Key Results
| Metric | TPE + IVIG Group | Weekly TPE Group | Sham Group |
|---|---|---|---|
| Biological age reduction (composite) | −2.61 years | −1.32 years | Worsened |
| Immune profile | T cells, NK cells, monocytes shifted toward youthful profile | Moderate changes | Aged |
| Proteomic rejuvenation | Strongest (proteostasis, senescence, inflammaging markers) | Moderate | — |
| Durability | Benefit diminished by time point 3 (2 months post-treatment) | Similar waning | — |
Swipe table →
Critical Observations
- IVIG may be the active ingredient: The study lacked an IVIG-only arm, making it impossible to determine if IVIG or TPE was driving the effect. The IVIG component may be more potent than the plasma exchange itself.
- Benefits were transient: Effects were strongest at the first post-treatment time point and diminished at the second, suggesting "potential compensatory mechanisms that mitigate the anti-aging effects after multiple sessions."
- Sicker patients responded more: Participants in poorer health (measured by monocyte and platelet levels) were stronger responders. Healthy individuals showed minimal benefit.
- Baseline variability: Different clocks showed different baselines across groups, complicating interpretation.
- Small sample size: N=44 across 4 groups means ~11 per group — underpowered for robust statistical conclusions after correction for 36 clocks.
04Mechanism of Action
How TPE Works Mechanically
TPE (also called plasmapheresis) is an FDA-cleared medical procedure: 1. Blood is withdrawn from the patient 2. A centrifuge or membrane separator separates plasma from cellular components (RBCs, WBCs, platelets) 3. Plasma is discarded 4. Cellular components are returned to the patient mixed with replacement fluid (5% albumin in saline, or donor plasma/IVIG) 5. Process removes approximately 1.0–1.5 plasma volumes per session
What TPE Removes
| Factor Category | Examples | Aging Relevance |
|---|---|---|
| SASP proteins | IL-6, IL-8, TNF-α, TGF-β, MMPs | Drive inflammaging, tissue degradation |
| Autoantibodies | ANA, anti-citrullinated protein | Increase with age, drive autoimmunity |
| Pro-aging peptides | CCL11/eotaxin, β2-microglobulin | Impair neurogenesis, cognitive function |
| Lipotoxic factors | Oxidized LDL, ceramides | Drive metabolic dysfunction |
| Environmental toxins | Microplastics, PFAS, heavy metals | Accumulate over decades |
| Inflammatory mediators | CRP, complement proteins | Chronic low-grade inflammation |
Swipe table →
IVIG Mechanism (If Combined)
IV immunoglobulin (IVIG) is a pooled preparation of IgG from thousands of donors: - Provides natural antibodies against senescent cell surface markers - Immunomodulatory effects: regulates Fc receptors, neutralizes autoantibodies - May accelerate clearance of senescent cells via antibody-dependent cellular cytotoxicity (ADCC) - Contains anti-idiotypic antibodies that suppress autoimmune responses
05Doses in studies
Standard Medical TPE (Established)
- Volume exchanged: 1.0–1.5 plasma volumes (~3L for average adult)
- Duration: 1.5–2 hours per session
- Replacement fluid: 5% albumin in normal saline (standard) or fresh frozen plasma
- Frequency: Typically 1–3 sessions per week for acute conditions
- Access: Large-bore peripheral IV or central venous catheter
- Anticoagulation: Citrate (ACD-A) during procedure
Doses in studies
- Frequency options:
- Weekly for 6 months (less intensive)
- Biweekly (2x/week) for 3 months (more intensive)
- IVIG addition: 1–2 g/kg IVIG after select TPE sessions
- Monitoring: Epigenetic clocks (Horvath, GrimAge), immune panels, proteomics before/after
- Maintenance: Unknown; no established re-treatment interval
⚠️ Important: No established longevity TPE protocol exists. All current protocols are experimental. The Circulate Health trial design is the closest to evidence-based.
06Clinical Applications Beyond Longevity
TPE is FDA-approved and well-established for numerous conditions:
FDA-Approved Indications (ASFA Category I)
- Guillain-Barré syndrome — acute inflammatory demyelinating polyneuropathy
- Myasthenia gravis — autoimmune neuromuscular crisis
- Hyperviscosity syndrome — Waldenström's macroglobulinemia
- Thrombotic thrombocytopenic purpura (TTP)
- Goodpasture syndrome — anti-GBM disease
- Cryoglobulinemia
- Severe rheumatoid arthritis (refractory)
- Long COVID (emerging evidence)
Potential Longevity-Spanning Applications
| Application | Evidence Level | Mechanism |
|---|---|---|
| Biological age reduction | Emerging (1 RCT) | Removal of SASP/inflammatory factors |
| Autoimmune disease | Strong (approved use) | Removal of autoantibodies |
| Neurodegenerative disease | Investigational | Reduction of neuroinflammatory factors |
| Chronic inflammation | Investigational | CRP/cytokine reduction |
| Post-COVID syndrome | Emerging | Removal of spike protein, inflammatory mediators |
Swipe table →
07Risks and Side Effects
Common (5-20%)
- Hypocalcemia — citrate anticoagulant binds calcium; causes perioral tingling, paresthesias
- Hypotension — volume shifts during procedure
- Allergic reaction — to replacement fluid (albumin, IVIG)
- Access complications — hematoma, infection at IV site
Less Common (1-5%)
- Infection — related to IV access or immunosuppression from IVIG
- Hypogammaglobulinemia — repeated TPE depletes immunoglobulins (rationale for IVIG replacement)
- Bleeding — depletion of clotting factors (especially with albumin replacement vs. FFP)
- Transfusion reactions — if donor plasma used
Rare but Serious (<1%)
- Anaphylaxis — to IVIG or replacement fluid
- Cardiac arrhythmia — electrolyte disturbances
- Vascular injury — central line placement complications
- Hypersensitivity reactions — including ACE inhibitor-induced bradykinin-mediated reactions
Long-Term Repeated TPE Concerns
- Protein depletion — albumin, immunoglobulins, clotting factors
- Iron deficiency — small RBC loss with each procedure
- Fibrinogen depletion — bleeding risk
- Unknown long-term effects of chronic plasma renewal on homeostasis
08Companies and Clinical Landscape
| Entity | Approach | Status |
|---|---|---|
| Circulate Health | TPE + IVIG for longevity; FDA-cleared technology | Clinical-stage; first RCT published 2025 |
| Buck Institute | Academic collaborator on multi-omics analysis | Published landmark 2025 study |
| Private clinics | Off-label TPE protocols (various) | Unregulated; quality varies widely |
| Conboy Lab (UC Berkeley) | Basic science; neutral blood exchange research | Preclinical; developing small-molecule alternatives |
Swipe table →
Regulatory Status
- TPE procedure: FDA-cleared medical device (for specific indications)
- Longevity use: Off-label / experimental — not FDA-approved for anti-aging
- IVIG: FDA-approved for immunodeficiency, off-label for longevity
- Right-to-try laws (Montana 2025, others) may expand access to experimental protocols
09Cost and Accessibility
- Per TPE session: $1,500–$3,000 (US clinic prices)
- Typical longevity course: 12–24 sessions → $18,000–$72,000
- IVIG cost: $7,000–$15,000 per dose (adds significantly)
- Insurance: Does not cover longevity/off-label use
- Access: Requires specialized clinic with apheresis equipment and medical supervision
10Evidence Quality Summary
| Evidence Type | Status | Rating |
|---|---|---|
| Heterochronic parabiosis (animal) | Multiple labs, decades of data | Strong |
| Neutral blood exchange (animal) | Conboy lab, multiple studies | Moderate-Strong |
| TPE for medical conditions (human) | FDA-approved, extensive RCTs | Strong (for approved uses) |
| TPE for longevity (human) | 1 RCT (N=44), 2025 | Emerging |
| TPE + IVIG biological age reduction | 1 RCT, significant but transient | Preliminary |
| Long-term safety of repeated TPE | No data | Unknown |
Swipe table →
11Open Questions and Limitations
- Is TPE alone effective, or is IVIG the active ingredient? The 2025 trial had no IVIG-only arm — this is a critical gap.
- How durable are the effects? Benefits waned within months. What is the optimal re-treatment interval?
- Who benefits most? Sicker patients responded better in the trial — is TPE appropriate for healthy individuals?
- What is being removed vs. what should be removed? Multi-omics identified biomarkers but the specific causal agents of aging in plasma remain unclear.
- Can oral small-molecule alternatives replicate TPE? The Conboy lab is investigating compounds that neutralize pro-aging plasma factors without apheresis.
- Safety of decades-long repeated TPE? No longitudinal data exists for chronic use.
12Comparison with Other Rejuvenation Approaches
| Approach | Mechanism | Human Evidence | Cost | Accessibility |
|---|---|---|---|---|
| TPE + IVIG | Removes circulating pro-aging factors | 1 RCT (2025) | Very high | Low (specialized clinics) |
| Senolytics | Kills senescent cells | Multiple early RCTs | Low-Moderate | High (oral) |
| NAD+ precursors | Restores NAD+ levels | Multiple RCTs | Low | High (oral) |
| Rapamycin | mTOR inhibition | Clinical trials ongoing | Low | Moderate (prescription) |
| Young plasma infusion | Adds young factors | Ambrosia trial (controversial, halted) | Very high | Very low |
Swipe table →
13Connections
14Sources
- Fuentealba M, Kiprov D, Schneider K, et al. Multi-omics analysis reveals biomarkers that contribute to biological age rejuvenation in response to single-blinded randomized placebo-controlled therapeutic plasma exchange. Aging Cell . 2025;24(7):e70103. doi: 10.1111/acel.70103DOI 10.1111/acel.70103
- Conboy IM, Conboy MJ, Wagers AJ, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature . 2005;433(7027):760-764. PMID: 15716955PubMed 15716955
- Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature . 2011;477(7362):90-94. PMID: 21886162PubMed 21886162
- Rebo J, Mehdipour M, Gathwala R, et al. A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood. Nat Commun . 2016;7:13363. PMID: 27845773PubMed 27845773
- Sviercovich A, Mei X, Xie G, Conboy MJ, Conboy IM. The dominance of old blood, and age-related increase in protein production and noise. Ageing Research Reviews . 2024;101:102641. doi: 10.1016/j.arr.2024.102641DOI 10.1016/j.arr.2024.102641
- Chen C, et al. Small extracellular vesicles from young plasma reverse age-related functional declines by improving mitochondrial energy metabolism. Nat Aging . 2024. doi: 10.1038/s43587-024-00612-4DOI 10.1038/s43587-024-00612-4
15Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.